Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Alliance Contract Pharma Supports Eye Drug Approval | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Alliance Contract Pharma Supports Eye Drug Approval

FDA green lights first twice-daily, nano-milled ocular corticosteroid

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Contract development and manufacturing organization, Alliance Contract Pharma (ACP), said one of its clients received FDA approval for the first twice-daily ocular corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery.
 
ACP supported the development of this product through a range of phases: formulation development, clinical supply, process validation, FDA inspection and approval, and launch.
 
“The most rewarding aspect of the years of quality-driven hard work, is seeing the success of the client’s FDA approval and the positive impact on the company’s future,” said Benjamin Reed, vice president, manufacturing, Alliance Contract Pharma. “The thoughtful determination through all aspects of the drug life cycle enabled the ease of commercialization.”
 
ACP develops and manufactures a wide range of dosage forms, from discovery to distribution. 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters